Plotted by close date where disclosed, otherwise announcement. Select any marker to jump to the deal entry.
Three patterns show up across Danaher's deal book — what the team buys, how it pays, and how it integrates. The patterns are the throughline; the deals below are the evidence.
20 acquisitions. Each entry carries the deal value, financing structure, target revenue, executive commentary, and the original SEC filing — the evidence behind the patterns above.
Sybron Dental Specialties was a leading manufacturer of a broad range of consumables and small equipment for the dental professional, including the specialty markets of orthodontics, endodontics and implantology. approximately $2.0 billion ($47.00 per share cash tender offer, including transaction costs and net of cash acquired; ~$200 million of debt assumed).
The combination of Danaher and Sybron Dental makes very strong strategic and financial sense. Sybron's consumables and small equipment offering are a logical extension of Danaher's existing dental equipment portfolio and will allow us to more broadly serve the dental community.H. Lawrence Culp — Jr., President and CEO, Danaher Corporation
We firmly believe the transaction with Danaher serves the best interests of our shareholders and will provide numerous benefits for our employees and customers.Floyd W. Pickrell — Jr., Chief Executive Officer, Sybron Dental Specialties
Tektronix is a leading supplier of test, measurement and monitoring instrumentation, including oscilloscopes and related electronic test equipment. Danaher acquired Tektronix through Raven Acquisition Corp. under an Agreement and Plan of Merger dated October 14, 2007. approximately $2.8 billion ($38.00 per share cash tender offer).
Beckman Coulter develops, manufactures and markets products that simplify, automate and innovate complex biomedical testing. Its diagnostic systems are found in hospitals and other clinical settings worldwide and produce information used by physicians to diagnose disease, make treatment decisions and monitor patients; its life-science research instruments are used to study complex biological problems. approximately $6.8 billion ($83.50 per share cash tender offer; total enterprise value including debt assumed and net of cash acquired).
Beckman Coulter is an iconic company with a great brand, broad reach and technology leadership; well positioned in the markets it serves. Beckman provides an excellent complement to our existing Life Sciences & Diagnostics businesses.H. Lawrence Culp — Jr., President and CEO, Danaher Corporation
Pall is a leading global provider of filtration, separation and purification solutions that remove contaminants or separate substances from a variety of solids, liquids and gases, serving the broad spectrum of life sciences and industry. approximately $13.8 billion ($127.20 per share cash; total enterprise value including assumed debt and net of acquired cash).
Pall is a highly attractive business, with approximately 75% recurring revenues, mid-single digit organic growth and a solid margin profile. Pall will provide us a leading business with significant runway for expansion and strengthens our life sciences position in the strategically-attractive, high-growth biopharmaceutical market.Thomas P. Joyce — Jr., President and CEO, Danaher Corporation
GE Biopharma — renamed Cytiva at close — is a leading provider of instruments, consumables and software supporting the research, discovery, process development and manufacturing workflows of biopharmaceutical drugs, comprising process chromatography hardware and consumables, cell culture media, single-use technologies, development instrumentation and consumables, and service. approximately $21.4 billion cash purchase price (net purchase price ~$20 billion after anticipated tax benefits; ~17x expected 2019 EBITDA).
GE Biopharma is renowned for providing best-in-class bioprocessing technologies and solutions. This acquisition will bring a talented and passionate team as well as a highly innovative, industry-leading product suite to our Life Sciences portfolio, providing an excellent complement to our current biologics workflow solutions.Thomas P. Joyce — Jr., President and CEO, Danaher Corporation
Masimo Corporation is a leading specialty diagnostics provider of pulse oximetry and other patient monitoring solutions, primarily in acute care settings, with advanced sensor technology and AI-enabled monitoring. approximately $9.9 billion ($180.00 per share cash; total enterprise value including assumed indebtedness and net of acquired cash; ~18x estimated 2027 EBITDA).
We are excited to welcome the Masimo team to Danaher. We've followed this innovative company for many years and see it as an exceptional strategic fit for Danaher. Masimo is a leader in pulse oximetry and other patient monitoring solutions, which combined with its trusted brand and differentiated technology, will greatly strengthen our diagnostics franchise.Rainer M. Blair — President and Chief Executive Officer, Danaher Corporation
Masimo's advanced sensor technology and AI-enabled monitoring bring powerful new capabilities to our diagnostics portfolio. Integrating these strengths into Danaher will create meaningful opportunities to innovate for clinicians and improve decision making in critical settings.Julie Sawyer Montgomery — Executive Vice President for Diagnostics, Danaher
Danaher entered the water-quality sector in 1996 and acquired Hach Company in 1999, building a worldwide leader in water-quality instrumentation, consumables and services for municipal, industrial and laboratory water testing. approximately $325 million ($18.50 per share).
We entered the water quality sector in 1996 and have enhanced our geographical coverage and product and service breadth through subsequent acquisitions including Dr. Lange, Hach Company, and Viridor Instrumentation, which was acquired in February 2002.Danaher Corporation FY02 10-K — Item 1 Business description
Danaher earnings call (2015-10-22): solid core growth, earnings performance and free cash flow. In a weakening global macro environment, we saw the positive impact of the Danaher Business System across our portfolio. Our consistent pace of new product introductions and go to market initiatives led to mid single digit growth or better for several of our operating companies, including Hach, Trojan, ChemTreat, Gilbarco, Radiometer, SCIEX, Videojet and Matco. We're also making steady progress on the separation front. This quarter, we ...
Kollmorgen Corporation expanded Danaher's Motion platform with motors, drives and electro-optical/aerospace subsystems, marketed under the Kollmorgen Electro-Optical brand among others. approximately $325 million ($23.00 per share cash).
We entered the motion industry through the acquisition of Pacific Scientific Company in 1998, and have subsequently expanded our product and geographic breadth with various additional acquisitions, including American Precision Industries, Kollmorgen Corporation, the motion businesses of Warner Electric Company, and Thomson Industries.Danaher Corporation FY02 10-K — Item 1 Business description
Danaher acquired the Gilbarco retail-petroleum business and entered Product Identification through the February 2002 acquisition of Videojet (formerly Marconi Data Systems). approximately $325 million (acquired from Marconi plc).
Through the Gilbarco Veeder-Root business, Danaher is a leading worldwide provider of technologies and services for the retail/commercial petroleum market. ... Danaher entered the Product Identification market through the acquisition of Videojet (formerly known as Marconi Data Systems) in February 2002.Danaher Corporation FY02 10-K — Item 1 Business description
In 2005 Danaher acquired Leica Microsystems, a leading global provider of professional microscopes, founding what became its life-sciences instrumentation business. approximately $550 million enterprise value.
In 2005 the Company expanded its presence in the medical technologies segment through the acquisition of Leica Microsystems and three additional smaller acquisitions.Danaher Corporation FY05 10-K — Item 1 Business description
Danaher acquired Vision Systems Limited in 2006, strengthening its anatomical-pathology diagnostics business (later Leica Biosystems). approximately $520 million (A$3.75 / US$2.79 per share).
We have subsequently added to the medical technologies business through various acquisitions, most notably the acquisitions of Leica Microsystems in 2005 and Sybron Dental Specialties and Vision Systems Limited in 2006.Danaher Corporation FY06 10-K — Item 1 Business description
Danaher earnings call (2026-01-22): rategy, driving M&A, and creating an increasingly powerful pathology leader. Starting with core histology, that was our foothold in the pathology lab, and we've got a great position. I mean, all this work that the lab does, preparing the tissue sample, is very central to what they do. And then the advanced staining we added with the acquisition of Vision Systems, so these immunohistochemistry capabilities, which is a higher growth adjacency to that initial core histology play, and then now also ...
In 2010 Danaher acquired AB Sciex and Molecular Devices, adding mass spectrometry and bioanalytical measurement to its life-sciences instrumentation business. approximately $1.1 billion combined (acquired from MDS Inc. and Life Technologies).
Our life sciences instrumentation business was created in 2005 through the acquisition of Leica Microsystems and has been expanded through subsequent acquisitions, including the acquistions of AB Sciex and Molecular Devices in 2010.Danaher Corporation FY09 10-K — Item 1 Business description
Keithley Instruments, acquired in 2010, expanded Danaher's Test & Measurement business in precision electronic measurement. approximately $300 million ($21.60 per share cash).
We established our Test & Measurement business in 1998 through the acquisition of Fluke Corporation, and have expanded the business through numerous subsequent acquisitions, including the acquisition of Tektronix, Inc. in November 2007 and Keithley Instruments, Inc. in 2010.Danaher Corporation FY10 10-K — Item 1 Business description
In January 2011 Danaher agreed to acquire EskoArtwork, a full-service solutions provider for the digital packaging design and production market. approximately $470 million (EUR 350 million).
In January 2011, we announced the execution of a definitive agreement to acquire EskoArtwork, a leading full service solutions provider for the digital packaging design and production market.Danaher Corporation FY10 10-K — Item 1 Business description
Danaher completed a tender offer for Nobel Biocare Holding AG in December 2014, acquiring 97% of outstanding shares; Nobel Biocare is a leader in high-precision individualized dental prosthetics, biomaterials and digital treatment planning. approximately CHF 1.9 billion (~$1.9 billion), CHF 17.10 per share cash tender.
On December 11, 2014, the Company successfully completed its tender offer for the outstanding shares of common stock of Nobel Biocare Holding AG, acquiring 97% of the outstanding shares for an aggregate cash purchase price of approximately CHF 1.9 billion (approximately $1.9 billion based on exchange rates as of the date the shares of common stock were acquired) including debt assumed.Danaher Corporation FY14 10-K — acquisition note
Danaher acquired Cepheid in 2016 for ~$4.0 billion; Cepheid is a leading global molecular diagnostics company that develops, manufactures and markets accurate, easy-to-use molecular systems and tests, now part of Danaher's Diagnostics segment. approximately $4.0 billion ($53.00 per share cash; including assumed debt and net of acquired cash).
An indirect, wholly-owned subsidiary of the Company acquired all of the outstanding shares of common stock of Cepheid, a California corporation, for $53.00 per share in cash, for a total purchase price of approximately $4.0 billion, including assumed debt and net of acquired cash (the “Cepheid Acquisition”).Danaher Corporation FY16 10-K — acquisition note
Danaher earnings call (2017-12-14): as you see increases in those while you see us controlling and in many cases taking down our G and A costs as a percent of sales. Another year of consistently executing what we call the Danaher playbook. And finally, and certainly last but not least, our recent acquisitions, important acquisitions, significant deployment of capital acquisitions at Cepheid, at Pall, at Nobel, certainly with the addition of PhenomenaX in our Life Science platform, all off to a terrific start. But that wasn't all, ...
Danaher acquired Integrated DNA Technologies (IDT) in April 2018 for ~$2.1 billion; IDT is a privately-held manufacturer of custom DNA and RNA oligonucleotides serving academic, biopharmaceutical, biotechnology, agriculture, clinical-diagnostics and pharmaceutical-development markets. approximately $2.1 billion (net of cash acquired).
On April 13, 2018, the Company acquired Integrated DNA Technologies, Inc. (“IDT”), a privately-held manufacturer of custom DNA and RNA oligonucleotides ... for a purchase price of approximately $2.1 billion, net of cash acquired. IDT had revenues of approximately $260 million in 2017, and is now part of the Company's Life Sciences segment.Danaher Corporation FY18 10-K — acquisition note
Danaher acquired Aldevron in August 2021 for ~$9.6 billion; Aldevron manufactures high-quality plasmid DNA, mRNA and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications. approximately $9.6 billion cash purchase price.
On August 30, 2021, the Company acquired Aldevron, L.L.C. (“Aldevron”) for a cash purchase price of approximately $9.6 billion (the “Aldevron Acquisition”). Aldevron manufactures high-quality plasmid DNA, mRNA and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications.Danaher Corporation FY21 10-K — acquisition note
Danaher acquired Abcam plc in December 2023 for ~$5.6 billion; Abcam is a leading global supplier of protein consumables, including highly validated antibodies, reagents, biomarkers and assays addressing targets in biological pathways. approximately $5.6 billion cash purchase price ($24.00 per share).
On December 6, 2023, the Company acquired Abcam plc (“Abcam”) for a cash purchase price of approximately $5.6 billion (the “Abcam Acquisition”). Abcam is a leading global supplier of protein consumables, including highly validated antibodies, reagents, biomarkers and assays to address targets in biological pathways.Danaher Corporation FY23 10-K — acquisition note
In Q1 2004 Danaher founded its Medical Technology platform with the acquisition of Radiometer A/S, a leader in blood-gas and acute-care diagnostics. Danaher acquired 95.4% of the share capital.
In the first quarter of 2004 a fifth strategic platform, Medical Technology, was added to the segment through the acquisitions of substantially all of the outstanding shares of Radiometer A/S and the Gendex business of Dentsply International Inc. On January 27, 2004, Danaher acquired 95.4% of the share capital [of Radiometer].Danaher Corporation FY03 10-K — Item 1 Business description